SCHEMBL5407151

SCHEMBL5407151

NC(=O)c1cccc(C2(O)C3CCC2CN(Cc2cccnc2)C3)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 8/20 0.53
OPRK1 P41145 4/20 0.50
KCNH2 Q12809 1/20 0.50
OPRD1 P41143 1/20 0.43
PARP1 P09874 1/20 0.42
PARP2 Q9UGN5 1/20 0.42
ARG1 P05089 1/20 0.41
ARG2 P78540 1/20 0.41
F2 P00734 1/20 0.41
F10 P00742 1/20 0.41
VNN1 O95497 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
DRD4 P21917 1/20 0.41
CACNA1I Q9P0X4 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5406464 0.87 OPRM1 (0.58) OPRM1OPRK1KCNH2OPRD1ALDH1A1
SCHEMBL5407157 0.85 OPRM1 (0.47) OPRM1OPRK1OPRD1ALDH1A1MAPT
SCHEMBL5409573 0.83 OPRM1 (0.50) OPRM1OPRK1KCNH2OPRD1
SCHEMBL5403119 0.81 OPRM1 (0.52) OPRM1OPRK1KCNH2OPRD1DRD4
SCHEMBL5406334 0.81 DPP4 (0.49) OPRM1OPRK1OPRD1
SCHEMBL5398073 0.80 OPRM1 (0.59) OPRM1OPRK1KCNH2OPRD1PARP1
SCHEMBL5417254 0.80 OPRM1 (0.46) OPRM1OPRK1OPRD1
SCHEMBL5403259 0.80 OPRM1 (0.51) OPRM1OPRK1KCNH2OPRD1ALDH1A1
SCHEMBL5403311 0.79 OPRM1 (0.59) OPRM1OPRK1KCNH2OPRD1
SCHEMBL5406251 0.79 CXCR3 (0.47) OPRM1OPRK1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7241887-B2 3-azabicyclo[3.2.1]octane derivatives PFIZER INC (US) 2007-07-10 US claimed
EP-1615894-A2 3-AZABICYCLO 3.2.1 OCTANE DERIVATIVES Pfizer Products Inc. (US) 2006-01-18 EP claimed
WO-2004089908-A2 3-AZABICYCLO[3.2.1]OCTANE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-10-21 WO claimed
US-7241887-B2 3-azabicyclo[3.2.1]octane derivatives PFIZER INC (US) 2007-07-10 US disclosed
EP-1615894-A2 3-AZABICYCLO 3.2.1 OCTANE DERIVATIVES Pfizer Products Inc. (US) 2006-01-18 EP disclosed
US-20040259859-A1 3-Azabicyclo[3.2.1]octane derivatives PFIZER INC 2004-12-23 US disclosed
WO-2004089908-A2 3-AZABICYCLO[3.2.1]OCTANE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259859-A1 3-Azabicyclo[3.2.1]octane derivatives OPRD1, OPRK1, OPRM1 OPRM1 3/4885OPRK1 2/4885KCNH2 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.